Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Personalised Adaptive Medicine

Project description

A new drug formulation system for personalised medicine

Personalised drug formulations face scalability, cost and regulatory obstacles. This results in suboptimal treatment outcomes and the pervasive problem of polypharmacy-induced dosing errors. Moreover, the lack of technology for robust dosage-patient data collection impedes the promise of big data health IT systems. With this in mind, the EIC-funded PERAMEDIC project introduces a stand-alone drug formulation system for personalised medicine, featuring locally prepared, individually customised, segmented release polypills. This innovation integrates novel technologies, including personal release profiles, in situ 3D printing and ultra-precise multichannel powder dosing. The envisioned desktop-size device promises a revolution in drug delivery, starting in clinical settings and expanding to pharmacies and medical practices.

Objective

Personalised drug formulation is a hot topic but state of the art approaches are limited by low scalability, cost, and regulatory hurdles, while current polypill formulation efforts are hindered by liquid form or hot melt addition approaches, posing stability issues.

These bottlenecks carry a great societal price, as the synergic boost of drug combinations was recently demonstrated to reach significant improvement in treatment outcomes, while keeping active substances in the ideal physiological concentration window is known to maximise efficiency and reduce side effects. Also, polypharmacy is a real problem leading to dosing errors and significant loss in patient adherence. Finally, while Big Data Health IT system concepts on the far horizon hold potential to gather the large amount of reliable dosage-patient data required for evidence-based personalised medicine, the technology to deliver such data – well-tracked patient/dosing procedures with bi-directional digital information flow – is missing.

The PERAMEDIC project proposes to resolve these problems with a breakthrough solution: a stand-alone drug formulation system for personalised medicine, offering locally prepared, individually customised, segmented release polypills, with an inherently digital technology interface. The system relies on integrating several novel technologies: personal release profiles, in situ 3D printing of release matrix using adaptive toolpaths, and ultra-precise multichannel powder dosing of drugs into sealed microcompartments. The envisaged device would be a desktop-size pill/capsule printing machine, using canisters of powdered drugs and bioresorbable polymer matrix material. Application scenarios would be first clinical settings, then at later stage, pharmacy locations and medical practices such as GP’s office.

PERAMEDIC will deliver a lab-scale proof-of-concept prototype system of the functionally combined novel technologies, with a preview design of the future technology.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-PATHFINDEROPEN-01

See all projects funded under this call

Coordinator

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Net EU contribution
€ 836 250,00
Address
HANSASTRASSE 27C
80686 Munchen
Germany
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Research Organisations
Links
Total cost
€ 836 250,00

Participants (2)

Partners (3)